| Combination of | |
|---|---|
| Loteprednol | Corticosteroid |
| Tobramycin | Aminoglycoside antibiotic |
| Clinical data | |
| Trade names | Zylet |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Routes of administration | Ophthalmic |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Loteprednol/tobramycin, sold under the brand name Zylet, is a fixed-dose combination medication used for the treatment of inflammation of the eye.[1] It is a combination of loteprednol, as the etabonate, a corticosteroid; and tobramycin, an aminoglycoside antibiotic.[1] It is used as drops in the eye.[1]
Loteprednol/tobramycin was approved for medical use in the United States in December 2004.[1]
|
| |
|---|---|
| Glucocorticoids |
|
| Antiglucocorticoids |
|
| Synthesis modifiers |
|
| |
|
| |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30S |
| ||||||||||||||
| 50S |
| ||||||||||||||
| EF-G |
| ||||||||||||||
| |||||||||||||||
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
